Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer

Pancreatic cancer is the most lethal common solid malignancy. Systemic therapies are often ineffective, and predictive biomarkers to guide treatment are urgently needed. We generated a pancreatic cancer patient-derived organoid (PDO) library that recapitulates the mutational spectrum and transcriptional subtypes of primary pancreatic cancer. New driver oncogenes were nominated and transcriptomic analyses revealed unique clusters. PDOs exhibited heterogeneous responses to standard-of-care chemotherapeutics and investigational agents. In a case study manner, we found that PDO therapeutic profiles paralleled patient outcomes and that PDOs enabled longitudinal assessment of chemosensitivity and evaluation of synchronous metastases. We derived organoid-based gene expression signatures of chemosensitivity that predicted improved responses for many patients to chemotherapy in both the adjuvant and advanced disease settings. Finally, we nominated alternative treatment strategies for chemorefractory PDOs using targeted agent therapeutic profiling. We propose that combined molecular and therapeutic profiling of PDOs may predict clinical response and enable prospective therapeutic selection. New approaches to prioritize treatment strategies are urgently needed to improve survival and quality of life for patients with pancreatic cancer. Combined genomic, transcriptomic, and therapeutic profiling of PDOs can identify molecular and functional subtypes of pancreatic cancer, predict therapeutic responses, and facilitate precision medicine for patients with pancreatic cancer. .

Citing Articles

MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC.

Fiorini E, Malinova A, Schreyer D, Pasini D, Bevere M, Alessio G Nature. 2025; .

PMID: 40074906 DOI: 10.1038/s41586-025-08721-9.

Establishing a cryopreserved biobank of living tumor tissues for drug sensitivity testing.

Chen P, Zhou J, Chu X, Feng Y, Zeng Q, Lei J Bioact Mater. 2025; 46:582-596.

PMID: 40061435 PMC: 11889390. DOI: 10.1016/j.bioactmat.2024.09.008.

Optimizing drug sensitivity assays in patient-derived tumor organoids: a comparison of IC50 estimation methods and experimental parameters.

Chen Y, Zhang J, Zhang B, Lee H, Xie S, Shen W Biol Methods Protoc. 2025; 10(1):bpaf012.

PMID: 40060949 PMC: 11890276. DOI: 10.1093/biomethods/bpaf012.

Organoid drug profiling identifies methotrexate as a therapy for SCCOHT, a rare pediatric cancer.

Kim S, de Weert T, Vermeulen M, Ringnalda F, Kester L, Zsiros J Sci Adv. 2025; 11(9):eadq1724.

PMID: 40009666 PMC: 11864178. DOI: 10.1126/sciadv.adq1724.

Establishing Pancreatic Cancer Organoids from EUS-Guided Fine-Needle Biopsy Specimens.

Wang M, Gao C, Huang X, Wang M, Zhang S, Gao X Cancers (Basel). 2025; 17(4).

PMID: 40002285 PMC: 11852484. DOI: 10.3390/cancers17040692.

References

Pritchard C, Smith C, Salipante S, Lee M, Thornton A, Nord A . ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing. J Mol Diagn. 2012; 14(4):357-66. PMC: 3391416. DOI: 10.1016/j.jmoldx.2012.03.002. View

Zhang Y, Ng P, Kucherlapati M, Chen F, Liu Y, Tsang Y . A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations. Cancer Cell. 2017; 31(6):820-832.e3. PMC: 5502825. DOI: 10.1016/j.ccell.2017.04.013. View

Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

Ritz C, Baty F, Streibig J, Gerhard D . Dose-Response Analysis Using R. PLoS One. 2015; 10(12):e0146021. PMC: 4696819. DOI: 10.1371/journal.pone.0146021. View

Shen R, Seshan V . FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. 2016; 44(16):e131. PMC: 5027494. DOI: 10.1093/nar/gkw520. View

Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, OReilly T . The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell. 2005; 120(6):747-59. DOI: 10.1016/j.cell.2004.12.040. View

Collisson E, Sadanandam A, Olson P, Gibb W, Truitt M, Gu S . Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011; 17(4):500-3. PMC: 3755490. DOI: 10.1038/nm.2344. View

Li B, Dewey C . RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics. 2011; 12:323. PMC: 3163565. DOI: 10.1186/1471-2105-12-323. View

Hessmann E, Patzak M, Klein L, Chen N, Kari V, Ramu I . Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer. Gut. 2017; 67(3):497-507. PMC: 5868285. DOI: 10.1136/gutjnl-2016-311954. View

10.

Provenzano P, Cuevas C, Chang A, Goel V, Von Hoff D, Hingorani S . Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012; 21(3):418-29. PMC: 3371414. DOI: 10.1016/j.ccr.2012.01.007. View

11.

Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y . FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364(19):1817-25. DOI: 10.1056/NEJMoa1011923. View

12.

Khorana A, Mangu P, Berlin J, Engebretson A, Hong T, Maitra A . Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016; 34(21):2541-56. DOI: 10.1200/JCO.2016.67.5553. View

13.

Winter J, Cameron J, Campbell K, Arnold M, Chang D, Coleman J . 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg. 2006; 10(9):1199-210. DOI: 10.1016/j.gassur.2006.08.018. View

14.

Gu Z, Eils R, Schlesner M . gtrellis: an R/Bioconductor package for making genome-level Trellis graphics. BMC Bioinformatics. 2016; 17:169. PMC: 4835841. DOI: 10.1186/s12859-016-1051-4. View

15.

Neoptolemos J, Palmer D, Ghaneh P, Psarelli E, Valle J, Halloran C . Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017; 389(10073):1011-1024. DOI: 10.1016/S0140-6736(16)32409-6. View

16.

Skidmore Z, Wagner A, Lesurf R, Campbell K, Kunisaki J, Griffith O . GenVisR: Genomic Visualizations in R. Bioinformatics. 2016; 32(19):3012-4. PMC: 5039916. DOI: 10.1093/bioinformatics/btw325. View

17.

Wang J, Mullighan C, Easton J, Roberts S, Heatley S, Ma J . CREST maps somatic structural variation in cancer genomes with base-pair resolution. Nat Methods. 2011; 8(8):652-4. PMC: 3527068. DOI: 10.1038/nmeth.1628. View

18.

Von Hoff D, Ervin T, Arena F, Chiorean E, Infante J, Moore M . Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369(18):1691-703. PMC: 4631139. DOI: 10.1056/NEJMoa1304369. View

19.

Dobin A, Davis C, Schlesinger F, Drenkow J, Zaleski C, Jha S . STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2012; 29(1):15-21. PMC: 3530905. DOI: 10.1093/bioinformatics/bts635. View

20.

Jacobetz M, Chan D, Neesse A, Bapiro T, Cook N, Frese K . Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut. 2012; 62(1):112-20. PMC: 3551211. DOI: 10.1136/gutjnl-2012-302529. View